Scott Alexander explores Hallucinogen Persisting Perception Disorder (HPPD) and other conditions where drugs cause permanent effects, discussing potential mechanisms and their implications.

Scott explores the theory that clozapine's unique effectiveness in treating schizophrenia may be due to its combined action on dopamine and glutamate systems, potentially opening avenues for safer treatments.

Scott Alexander argues that the 33% rate of post-marketing safety events for FDA-approved drugs is not necessarily concerning and explains why post-marketing surveillance is a normal part of drug safety monitoring.

Scott Alexander criticizes websites that misleadingly suggest drug side effects by scraping FDA data, potentially causing patients to stop taking necessary medications.

Scott examines how rare but severe drug side effects often lead to underprescription compared to drugs with common but less severe side effects, potentially resulting in suboptimal patient care.